

Atezolizumab IMpower010

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Not qualified for an ESMO-MCBS credit



Serious and disabling adverse effects



Other adjustments



Atezolizumab IMpower010

SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies
Therapeutic Indication: Adjuvant treatment following resection and platinum-based ChT for adult patients with Stage II to IIIA NSCLC whose tumors have PD-L1 expression on $\geq 1\%$ of tumor cells
Experimental Arm: Atezolizumab
Control Arm: Best supportive care



